SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins

SIGA Technologies (Nasdaq: SIGA) reported Q2 2026 revenue of $41.0 million, down about 49% from $81.1 million a year earlier, while diluted EPS fell to $0.17 from $0.49. Lower TPOXX product sales drove the decline, and a different product mix compressed margins despite deliveries to both U.S. and international customers.

Core Earnings Data

Product sales remained SIGA’s primary revenue source, falling about 52% to $37.9 million. Research and development revenue increased to $3.1 million, but its smaller contribution was insufficient to offset the product-sales decline.

Profit contracted faster than revenue. Operating income fell about 70%, and operating margin narrowed by 22.4 percentage points, reflecting the lower revenue base and differences in the mix of products delivered.

For the first six months of 2026, revenue was $47.2 million versus $88.2 million in the prior-year period. First-half net income declined to $9.0 million from $35.1 million, with diluted EPS falling to $0.13 from $0.49.

TPOXX Deliveries and Customer Mix

SIGA delivered approximately $37 million of TPOXX to three customers during the quarter. That included about $24 million of IV TPOXX supplied to the U.S. strategic national stockpile and $13 million of oral TPOXX delivered to two international customers.

The U.S. deliveries completed the final procurement order under the 19C contract. International sales covered customers in Europe and the Asia-Pacific region, supporting SIGA’s effort to diversify TPOXX sales across geographies, customers, and formulations.

The quarter nevertheless remained dependent on a limited number of government and public-health customers. Because revenue recognition is linked to procurement orders and product deliveries, the timing and composition of those orders can produce substantial differences between reporting periods.

Product Mix Amplified the Revenue Decline

Cost of sales and supportive services decreased to $17.6 million from $25.6 million, but this reduction was much smaller than the decline in related product revenue. The margin calculated from product sales and supportive-services revenue less the associated cost fell to approximately 53.6% from 67.7%.

That change flowed through to operating profitability. SG&A expense was relatively stable at $5.1 million compared with $5.5 million, while R&D expense was nearly unchanged at $4.4 million. With these expenses moving only modestly, the lower product contribution and less favorable mix had a larger effect on operating income. SIGA specifically attributed differences in operating margin between periods to product mix.

Cash and Balance Sheet

SIGA ended June with $117.6 million of cash and cash equivalents, down from $155.0 million at the end of 2025. The company also paid a special cash dividend of $0.60 per share on April 23, 2026, providing important context for the decline in cash, although the release did not include a cash flow statement that would separate operating and financing uses.

Inventory decreased about 16% to $41.1 million, while accounts receivable rose to $7.2 million from $3.3 million. Deferred IV TPOXX revenue, which stood at $10.24 million at the end of 2025, was zero at June 30. Total liabilities declined to $10.4 million from $20.6 million over the same period.

Risks Investors Need to Watch

• U.S. procurement continuity: The final procurement order under the 19C contract has been completed. Future U.S. product volume depends on SIGA obtaining additional government contracts or orders.
• International market development: International oral TPOXX deliveries contributed $13 million this quarter, but SIGA describes the international biodefense market as nascent, making the durability and scale of future demand uncertain.
• Margin sensitivity to product mix: The quarter demonstrated that different formulations and customer orders can materially change product and operating margins, even when SIGA continues to make deliveries.
• Delivery timing and supply-chain execution: Revenue depends on coordination among customers, contract manufacturers, and other vendors. Delayed procurement decisions or deliveries could shift revenue between reporting periods.

Summary

SIGA remained profitable in Q2 2026 and delivered TPOXX across U.S. and international markets, but lower product sales and a less favorable delivery mix caused revenue and earnings to fall sharply from the prior year. The next major issues are whether new U.S. procurement activity replaces the completed 19C order, whether international demand continues to develop, and how future product mix affects margins.